Treatment: lithium
BioMG follows French guidelines. Adapt it to the guidelines and the tests available where you practise.
Pre-treatment tests
Fasting laboratory tests
- FBC
- Serum electrolytes
- Serum creatinine with eGFR
- Serum calcium
- AST
- ALT
- GGT
- Alkaline phosphatase
- Serum bilirubin
- Fasting plasma glucose
- Lipid profile
- TSH
- β-hCGif neededWoman of childbearing potential: make sure she is not pregnant and start effective contraception before treatment [2].
- PTH (if serum calcium raised)if needednon-French guidelineThe Netherlands measures serum calcium and PTH before lithium, then twice a year (nephrologists, 2013, taken up by the 2026 guideline) [3,4]; CANMAT/ISBD and a 2026 review recommend looking for hyperparathyroidism if serum calcium rises [5,6]. The French SmPC and ALD 23 do not provide for this test [2,7]. Hyperparathyroidism: see the page “Hypercalcaemia”.
Urine tests
- Urine albumin:creatinine ratio or protein:creatinine ratio in non-diabetic patients
- Urine albumin:creatinine ratio in diabetic patients
Starting lithium: first three months
Laboratory tests to be done in the morning, 12 h after the last lithium dose
- Serum lithium
to be done every week in the first month, then every month until the end of the 3rd month, i.e.
- in 1 week
- in 2 weeks
- in 3 weeks
- in 4 weeks
- in 8 weeks
- in 12 weeks
At the 3-month (12-week) tests, add
- TSH
Monitoring tests (every 6 months)
Laboratory tests to be done in the morning, 12 h after the last lithium dose
- Serum lithium
- Serum electrolytes
- Serum creatinine with eGFR
- TSH
- serum calciumLong-term monitoring: lithium can cause hypercalcaemia through hyperparathyroidism.
- PTH (if serum calcium raised)if needednon-French guidelineThe Netherlands measures serum calcium and PTH before lithium, then twice a year (nephrologists, 2013, taken up by the 2026 guideline) [3,4]; CANMAT/ISBD and a 2026 review recommend looking for hyperparathyroidism if serum calcium rises [5,6]. The French SmPC and ALD 23 do not provide for this test [2,7]. Hyperparathyroidism: see the page “Hypercalcaemia”.
- urine protein:creatinine ratio on a spot urine sampleif neededLong-term renal follow-up: proteinuria is sought before treatment [2] and the urine protein or albumin:creatinine ratio is part of the follow-up listed in ALD 23 [7].
Also consider
Do not order
- Free T4, free T3 as routine monitoring: TSH alone is enough as first-line (reflex tests only if it is abnormal) [16].
Starting lithium with TERALITHE® 250mg
Laboratory tests to be done in the morning, 12 h after the last lithium dose
- Serum lithium
- twice a week, until a concentration between 0.5 and 0.8 mEq/L is reached
Starting lithium with TERALITHE LP® 400mg (prolonged release)
Laboratory tests to be done in the morning, 12 h after the last lithium dose
- Serum lithium
- on D7, D14 and, if necessary, D21, until a concentration between 0.8 and 1.2 mEq/L is reached
Situation at risk of overdose (dehydration, new drug)
Laboratory tests 5 to 7 days after the change (without delay if signs of overdose)
- Serum lithium
- Serum electrolytes
- Serum creatinine with eGFR
Older person (60 years and over): monitoring
Every 3 to 6 months (serum lithium in the morning, 12 h after the last dose)
- Serum lithium
- Serum creatinine with eGFR
- Urea
Every 6 to 12 months, fasting
- TSH
- Serum calcium
- Fasting plasma glucose
- Lipid profile
Every year
- FBC
Sources (18)
- Geographical disparities in prescription practices of lithium and clozapine: a community-based study. Acta Psychiatr Scand 2016 (auteurs non vérifiés ; résumé lu via Europe PMC).
- ANSM, Base de données publique des médicaments. Résumé des caractéristiques du produit TERALITHE 250 mg, comprimé sécable (rubriques 4.2 à 4.9), dernière mise à jour le 29/09/2026, consulté le 11 octobre 2026.
- Nederlandse Vereniging voor Psychiatrie (NVvP). Richtlijn Bipolaire stoornissen, module « Lithium bij bipolaire stoornis ». Publiée et jugée valide le 24 mars 2026.
- Nederlandse federatie voor Nefrologie. Richtlijn Renale bijwerkingen chronisch lithiumgebruik. Septembre 2013.
- Yatham LN, Kennedy SH, Parikh SV, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder. Bipolar Disord. 2018;20(2):97-170.
- Shahraki RA, Meehan AD, Wallin G, Daskalakis K. Lithium-associated hyperparathyroidism: a systematic review of prevalence and surgical outcomes. Langenbecks Arch Surg. 2026;411(1).
- Haute Autorité de santé. ALD n° 23 : troubles bipolaires. Liste des actes et prestations, 2009.
- National Institute for Health and Care Excellence. Bipolar disorder: assessment and management. Clinical guideline CG185, 2014, mise à jour du 2 septembre 2025, recommandations 1.2.12 et 1.10.14 à 1.10.24.
- NHS Specialist Pharmacy Service. Lithium monitoring. Dernière mise à jour le 6 décembre 2024.
- Bundesärztekammer (BÄK), Kassenärztliche Bundesvereinigung (KBV), Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF). Nationale VersorgungsLeitlinie Unipolare Depression – Langfassung, Version 3.2, 2022 (révision de juillet 2023), AWMF-Register-Nr. nvl-005 (tableau 30).
- Department of Veterans Affairs, Department of Defense. VA/DoD Clinical Practice Guideline for Management of Bipolar Disorder. Version 2.0, mai 2023.
- ANSM, Base de données publique des médicaments. Résumé des caractéristiques du produit TERALITHE LP 400 mg, comprimé sécable à libération prolongée (rubrique 4.2), dernière mise à jour le 29/09/2026, consulté le 11 octobre 2026.
- Haute Autorité de santé. Prise en charge des hypothyroïdies chez l'adulte. Recommandation de bonne pratique, mars 2023 (§ 3.2.8).
- Malhi GS, Bell E, Outhred T, Berk M. Lithium therapy and its interactions. Aust Prescr. 2020;43(3):91-93.
- Kibirige D, Luzinda K, Ssekitoleko R. Spectrum of lithium induced thyroid abnormalities: a current perspective. Thyroid Res. 2013;6(1):3.
- Assurance maladie. Nomenclature des actes de biologie médicale (NABM), version 105 : actes 1208 (TSH) et 0557 (lithium : lithiémie sérique ou érythrocytaire).
- Shulman KI, Almeida OP, Herrmann N, et al. Delphi survey of maintenance lithium treatment in older adults with bipolar disorder: an ISBD task force report. Bipolar Disord. 2019;21(2):117-123.
- National Institute for Health and Care Excellence. Depression in adults: treatment and management. NICE guideline NG222, 29 juin 2022 (recommandations sur le lithium en association).